Thera-SAbDab

ZINLIRVIMAB

>   Structural Summary
TherapeuticZinlirvimab
TargetHIV-1 gp120 V3
Heavy ChainQVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS
Light ChainSYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL
100% seqID Fv Structure6ccb [Fvs: DE, HL], 6okp [Fvs: KL], 6orn [Fvs: AB, FI, OP], 6udj [Fvs: AR, KL, QB], 6udk [Fvs: AB, FI, OP], 6v8z [Fvs: DE, JK, PQ], 7ucf [Fvs: HL], 7ucg [Fvs: HL, JK, QR], 7ugn [Fvs: MP, NQ, OR], 7ugo [Fvs: MP, NQ, OR], 7ugp [Fvs: MP, NQ, OR], 7ugq [Fvs: MP, NQ, OR]
99% seqID Fv Structure5t3x [Fvs: HL], 5t3z [Fvs: HL]
95-98% seqID Fv Structure4fq2 [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Zinlirvimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 96.58%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 100J 100K 100L 100M 100N 100O 100P 101 102 103 104 105 106 107 108 109 110 111 112 113
zinlirvimab Q V Q L Q E S G P G L V K P S E T L S V T C S V S G D S M N N Y Y W T W I R Q S P G K G L E W I G Y I S D R E S A T Y N P S L N S R V V I S R D T S K N Q L S L K L N S V T P A D T A V Y Y C A T A R R G Q R I Y G V V S F G E F F Y Y Y S M D V W G K G T T V T V S S
5t3x Q V Q L Q E S G P G L V K P S E T L S V T C S V S G D S M N N Y Y W T W I R Q S P G K G L E W I G Y I S D R E S A T Y N P S L N S R V V I S R D T S K N Q L S L K L N S V T P A D T A V Y Y C A T A R R G Q R I Y G V V S F G E F F Y Y Y S M D V W G K G T T V T V S S

Light chain

Position 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 66A 66B 66C 67 68 68A 68B 68C 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 95C 96 97 98 99 100 101 102 103 104 105 106 107
zinlirvimab L S V A L G E T A R I S C G R Q A L G S R A V Q W Y Q H R P G Q A P I L L I Y N N Q D R P S G I P E R F S G T P - - - D I N F G T R A T L T I S G V E A G D E A D Y Y C H M W D S R S G F S W S F G G A T R L T V L
5t3x L S V A L G E T A R I S C G R Q A L G S R A V Q W Y Q H R P G Q A P I L L I Y N N Q D R P S G I P E R F S G T P D I N F G - - - T R A T L T I S G V E A G D E A D Y Y C H M W D S R S G F S W S F G G A T R L T V L
Sequence identity: 96.58%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 100J 100K 100L 100M 100N 100O 100P 101 102 103 104 105 106 107 108 109 110 111 112 113
zinlirvimab Q V Q L Q E S G P G L V K P S E T L S V T C S V S G D S M N N Y Y W T W I R Q S P G K G L E W I G Y I S D R E S A T Y N P S L N S R V V I S R D T S K N Q L S L K L N S V T P A D T A V Y Y C A T A R R G Q R I Y G V V S F G E F F Y Y Y S M D V W G K G T T V T V S S
5t3z Q V Q L Q E S G P G L V K P S E T L S V T C S V S G D S M N N Y Y W T W I R Q S P G K G L E W I G Y I S D R E S A T Y N P S L N S R V V I S R D T S K N Q L S L K L N S V T P A D T A V Y Y C A T A R R G Q R I Y G V V S F G E F F Y Y Y S M D V W G K G T T V T V S S

Light chain

Position 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 66A 66B 66C 67 68 68A 68B 68C 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 95C 96 97 98 99 100 101 102 103 104 105 106 107
zinlirvimab L S V A L G E T A R I S C G R Q A L G S R A V Q W Y Q H R P G Q A P I L L I Y N N Q D R P S G I P E R F S G T P - - - D I N F G T R A T L T I S G V E A G D E A D Y Y C H M W D S R S G F S W S F G G A T R L T V L
5t3z L S V A L G E T A R I S C G R Q A L G S R A V Q W Y Q H R P G Q A P I L L I Y N N Q D R P S G I P E R F S G T P D I N F G - - - T R A T L T I S G V E A G D E A D Y Y C H M W D S R S G F S W S F G G A T R L T V L
Sequence identity: 94.44%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 100J 100K 100L 100M 100N 100O 100P 101 102 103 104 105 106 107 108 109 110 111 112 113
zinlirvimab Q V Q L Q E S G P G L V K P S E T L S V T C S V S G D S M N N Y Y W T W I R Q S P G K G L E W I G Y I S - - D R E S A T Y N P S L N S R V V I S R D T S K N Q L S L K L N S V T P A D T A V Y Y C A T A R R G Q R I Y G V V S F G E F F Y Y Y S M D V W G K G T T V T V S S
4fq2 Q V Q L Q E S G P G L V K P S E T L S V T C S V S G D S M N N Y Y W T W I R Q S P G K G L E W I G Y I S D R E - - S A T Y N P S L N S R V V I S R D T S K N Q L S L K L N S V T P A D T A V Y Y C A T A R R G Q R I Y G V V S F G E F F Y Y Y S M D V W G K G T T V T V S S

Light chain

Position 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 66A 66B 66C 67 68 68A 68B 68C 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 95C 96 97 98 99 100 101 102 103 104 105 106 107
zinlirvimab L S V A L G E T A R I S C G R Q A L G S R A V Q W Y Q H R P G Q A P I L L I Y N N Q D R P S G I P E R F S G T P - - - D I N F G T R A T L T I S G V E A G D E A D Y Y C H M W D S R S G F S W S F G G A T R L T V L
4fq2 L S V A L G E T A R I S C G R Q A L G S R A V Q W Y Q H R P G Q A P I L L I Y N N Q D R P S G I P E R F S G T P D I N F G - - - T R A T L T I S G V E A G D E A D Y Y C H M W D S R S G F S W S F G G A T R L T V L
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Active
Recorded Developmental Technology
INN Year Proposed2022
INN Year RecommendedNone
Companies InvolvedGilead
Conditions Approvedna
Conditions ActiveHIV-1 infections, AIDS
Conditions Discontinuedna
NotesVL sequence truncation prevents 3D modelling with ABodyBuilder2

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy